Medicine
Spritam 250 mg tablet for oral suspension
Spritam 250 mg tablet for oral suspension is a prescription medicine containing Levetiracetam for oral use, marketed by Aprecia Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Key facts
- Active ingredient (INN)
- Levetiracetam
- Brand
- Spritam
- Strength
- 250 mg
- Dosage form
- Tablet for oral suspension
- Route
- Oral
- Packs
- 6 blister pack, 60 blister pack
- Marketing authorisation holder
- Aprecia Pharmaceuticals
- Manufacturer
- Aprecia Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N03AX14 Levetiracetam
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 February 2016
- Identifiers
- RxCUI 1736037, 1736044, 1736045 +5DailyMed set ID be651c31-383f-11e4-916c-0800200c9a66NDC 43485-101Application NDA207958
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 6 blister pack in 1 carton / 1 tablet, for suspension in 1 blister pack | 43485-101-03 | Aprecia Pharmaceuticals | 31 January 2026 |
| 60 blister pack in 1 carton / 1 tablet, for suspension in 1 blister pack | 43485-101-60 | Aprecia Pharmaceuticals | 5 February 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Levetiracetam 250 mg tablet for oral suspension.
Other strengths and forms of Levetiracetam
Clinical summary
Levetiracetam is a prescription medicine indicated for the treatment of partial-onset seizures in patients 1 month of age and older, among other approved uses. MedsAcross supplies Levetiracetam for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LevetiracetamFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Keppra prescribing information (UCB) · U.S. National Library of Medicine, DailyMed
- Keppra: European public assessment report (EPAR) · European Medicines Agency
- Levetiracetam Accord: European public assessment report (EPAR) · European Medicines Agency
Need Spritam 250 mg tablet for oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.